Drug intelligence / Profile preview

ampicillin + gentamicin + clindamycin + metronidazole + ceftazidime

Development stage
Unknown
Lead developer
GSK
Modality
Small Molecules
Administration
Intravenous, Intramuscular
01

Overview

This is a combination of five antibiotics—ampicillin, gentamicin, clindamycin, metronidazole, and ceftazidime—used together to provide extremely broad-spectrum antibacterial coverage. Each component targets different classes of bacteria or mechanisms: - Ampicillin is a beta-lactam antibiotic effective against many Gram-positive and some Gram-negative organisms. - Gentamicin is an aminoglycoside antibiotic primarily active against aerobic Gram-negative bacteria. - Clindamycin is a lincosamide antibiotic with activity against anaerobic bacteria and some Gram-positive cocci. - Metronidazole is particularly effective against anaerobic bacteria and certain protozoa by disrupting DNA synthesis. - Ceftazidime is a third-generation cephalosporin with strong activity against many Gram-negative organisms (notably Pseudomonas aeruginosa) but less so for most anaerobes[1][2][3]. This combination may be used in severe polymicrobial infections where multidrug-resistant or mixed aerobic/anaerobic pathogens are suspected.

02

Targets

23S rRNA (23S ribosomal RNA)Bacterial RibosomePenicillin-binding protein 3 and other penicillin-binding proteinsNeuraminidaseDNA polymerase familyPBP1A (Penicillin-binding protein 1A)PBP1b (Penicillin-binding protein 1B)

Beyond the preview

Go deeper on ampicillin + gentamicin + clindamycin + metronidazole + ceftazidime.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ampicillin + gentamicin + clindamycin + metronidazole + ceftazidime.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call